Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector
Status:
Completed
Trial end date:
2014-06-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety, tolerability and immunogenicity of
Takeda's Tetravalent Dengue Vaccine Candidate (TDV) [previously DENVax] when administered
intradermally in varied dosing schedules and via different methods of administration
(conventional needle/syringe versus needle-free PharmaJet® injector).